🔎 Trials Near Me

Home › Non-Hodgkin Lymphoma › Minnesota › Rochester

Pag-aaral pangklinika para sa Non-Hodgkin Lymphoma sa Rochester, MN

14 pag-aaral para sa Non-Hodgkin Lymphoma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Rochester (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Nagre-recruitPhase 1/2
  • Mayo Clinic Rochester, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05006716

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Nagre-recruitPhase 1
  • Mayo Clinic - Rochester, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Nagre-recruitPhase 1
  • Mayo Clinic - Rochester, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07226843

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Nagre-recruitPhase 1/2
  • Mayo Clinic in Rochester, Minnesota, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06090539

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Nagre-recruitPhase 2
  • Research Site, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06526793

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Nagre-recruitPhase 1/2
  • Research Site, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07123454

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Nagre-recruitPhase 1/2
  • Mayo Clinic, Clinical Trials Referral Office, Rochester
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Nagre-recruitPhase 3
  • Mayo Clinic Rochester, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

Nagre-recruitPhase 2
  • Mayo Clinic, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Nagre-recruitPhase 1/2
  • Mayo Clinic, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 16, 2026 · NCT03328078

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Nagre-recruitObservasyonal na pag-aaral
  • Mayo Clinic, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06418204

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Nagre-recruitPhase 4
  • Mayo Clinic- Minnesota, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 2, 2026 · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Nagre-recruitPhase 4
  • Mayo Clinic- Minnesota, Rochester
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 2, 2026 · NCT06876662

Family Study of Lymphoproliferative Disorders

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • Mayo Clinic, Rochester
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Okt 14, 2025 · NCT00626496

Pag-aaral para sa Non-Hodgkin Lymphoma sa ibang lungsod

Iba pang pag-aaral sa Rochester

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.